NCT05327517 Surgery or Chemoradiotherapy for Cervical Esophageal Cancer
| NCT ID | NCT05327517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Cervical Esophageal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 192 participants |
| Start Date | 2022-04-10 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 192 participants in total. It began in 2022-04-10 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To compare surgery with definitive chemoradiotherapy for patients with resectable cervical esophageal squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria: * Patients with resectable cervical esophageal squamous cell carcinoma (cT1b-T4aN0-3M0); * Cervical esophageal cancers spreads upwards to involve the hypopharynx and downwards to involve the thoracic esophagus can also be included; * Aged 18-75 years; * Without any contraindication of operation; * Hemoglobin \>=90 g/L; Leukocytes \>=4.0x10\^9/L; Absolute neutrophil count \>=1.5x10\^9/L; Platelet \>=100x10\^9/L;Total bilirubin \<=1.5 ULN; ALT \<=2.5 ULN; AST \<=2.5 ULN; Serum creatinine \<=1.5 ULN or creatinine clearance rate \>=50 mL/min (Cocheroft-Gault);INR \<=1.5 ULN; APTT \<=1.5 ULN; * Without other malignancies; * Expected R0 resection; * ECOG PS 0-1; * Volunteered to participate in the study, signed the informed consent form. Exclusion Criteria: * Without other malignancies; * With mental diseases; * With hemorrhagic disease; * Inoperable patients; * Pregnant or lactating women; * Has a history of allergy to paclitaxel or cisplatin
Contact & Investigator
Jie He, MD
STUDY DIRECTOR
Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Frequently Asked Questions
Who can join the NCT05327517 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Cervical Esophageal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05327517 currently recruiting?
Yes, NCT05327517 is actively recruiting participants. Contact the research team at wangzhen@cicams.ac.cn for enrollment information.
Where is the NCT05327517 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05327517 clinical trial?
NCT05327517 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The principal investigator is Jie He, MD at Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. The trial plans to enroll 192 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.